Take Control of Your Gallium-68 Agents!
Helping you design and complete a new level of success!
What We Do
PROFITABILITY
PROFITABILITY
PROFITABILITY
At Five-Eleven Consulting we believe you should have more control over your Ga-68 radiopharmaceuticals: from patient scheduling, dose activity, and freedom from the associated costs for the receipt of a prepared dose from a radiopharmacy.
Higher departmental efficiency for patient care and physician access is our priority.
TECHNICAL
PROFITABILITY
PROFITABILITY
Five-Eleven Consulting will design and implement a specialized program to help your nuclear urology imaging department be more efficient and profitable. We will work with your personnel to create a turn-key program that will allow you to cut out the middleman.
EXPERTISE
PROFITABILITY
EXPERTISE
We have 50 years of combined radiopharmacy experience and believe Gallium-68 generators belong in the imaging centers. The 68-minute half-life and limitations of the drug require a sequence of events to work perfectly on a day-to-day basis. We have experience creating programs and implementing radiopharmacies and believe we can create an imaging program that works for you!
Germanium-68 / Gallium-68
About Gallium-68
Germanium-68 / Gallium-68 generators are becoming a normal asset owned by many nuclear pharmacies and imaging centers across the country. The Gallium-68 produced from the generator is an isotope that can be utilized by PET/CT departments for locating and determining metastasis of types of Prostate Cancer and Neuroendocrine Tumors. The number of manufacturers of these generators continues to grow and the ligands being attached to the isotope continue to lead to the development of theranostic opportunities. With the number of generator manufacturers growing, we want to ensure you are getting the one that best fits your needs.
Maintenance
The Germanium-68 / Gallium-68 generators are relatively easy to use with proper training. Maintenance includes ensuring Germanium-68 breakthrough is low, the generator has been recently eluted, and is under the maximum number of elutions.
The Future of PET
Allow us to help you help your patients!
It is no surprise that the utilization of PET radiopharmaceuticals is going to play a major role in determining the types of cancer, location of that cancer, and the rate of cancer metastases.
Why should imaging centers have to pay delivery fees, deal with failed cyclotron production runs, and traffic delays to take care of their patients when an option to produce patient doses in-house is available? You can create better care for your patients and give access to your physicians that few other locations have!